The cancer biomarker test market is driven by rising prevalence of cancer worldwide. World Health Organization (WHO) stated that cancer is one of the leading causes of mortality and morbidity worldwide, with approximately 14 Mn new cases in 2012. The number of new cases is expected to rise about 70% over the coming 2 decades. In addition, increase in awareness in public and healthcare professionals regarding early diagnostic procedures, rise in government and NGO’s funding for oncology are expected to bolster the cancer biomarker testing market. Furthermore, the development of companion diagnostics and recent breakthrough in detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the cancer biomarker test market. However, high cost for biomarker tests, low detection rates and regulatory policies are expected to hamper the cancer biomarker test market.A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-cancer-biomarker-testing-market/#ulp-4H8Z4LpNMLEuOnnx
Cancer biomarker testing market segmented based on type of cancer, application, bio molecule and end user
Based on type of cancer, cancer biomarker test market is segmented into
Cervical cancer
Lung Cancer
Collateral Cancer
Liver Cancer
Prostate Cancer
Breast Cancer
Others
Based on application, cancer biomarker test market is segmented into
Drug Discovery and Development
Personalised Medicine
Diagnosis
Others
Based on end-user, cancer biomarker test market is segmented into
Hospitals
Cancer diagnostic Centres
Research Institutes
Others
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-cancer-biomarker-testing-market/#ulp-c654SbFYO64MsOhu
The global cancer biomarker test market is expected to grow with significant CAGR during forecast period. Market players are carrying out collaborations, partnerships, and acquisitions as key development strategies to enhance the market share. For instance, in March 2017, Foundation Medicine and Bristol-Myers Squibb entered collaboration to understand tumour profile and its microenvironment to predict patient’s response to cancer immunotherapy. Using Foundation Medicine’s foundation genomic profiling assay, the firm will look at tumour mutational burden and microsatellite instability in patients enrolled in clinical trials for Bristol-Myers Squibb (BMS) cancer drugs.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-cancer-biomarker-testing-market/#ulp-14mlyhjMGhVjZqa3
Some of the players in cancer biomarker test market are Thermo Fisher Scientific (Affymetrix Inc.) (U.S.), Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (U.S.), Arquer Diagnostics Ltd. (U.K.), Illumina, Inc. (U.S.), Qiagen (Germany), Agilent Technologies (U.S.), Merck & Co. Inc. (U.S.), Becton Dickinson and Company (U.S.), and Hologic Inc. (U.S.) to name a few.
"Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free(US): +1-866-598-1553"